Novel bispecific antibody technology that connects tumor cells with myeloid cells, resulting in powerful and safe immune stimulation, targeted phagocytosis, and memory-like response via neoantigen presentation to elicit a durable long-lasting effect
Targeted Myeloid Engager and Phagocytosis Platform antibodies engage an activatory phagocytic receptor selectively expressed on myeloid cells, including tumor-associated macrophages (TAMs), dendritic cells (DCs), monocytes and myeloid-derived suppressor cells (MDSCs)
TAMs are a dominant immunosuppressive element in many cancers and are frequently associated with worse clinical outcomes. By directly repolarizing TAMs and engaging DCs to execute targeted phagocytosis, antigen presentation, and T cell activation, Dren Bio’s bispecific antibodies aim to expand the therapeutic benefit of immunotherapy and provide long-lasting responses